Anxiety disorder is a common and disabling condition that mostly begins during childhood, adolescence, and early adulthood (Craske & Stein, 2016). Anxiety is persistent and impairs daily functioning. Most anxiety disorders affect almost twice as many women as men. Anxiety mostly co-occurs with major depression, alcohol, substance-use disorders, and personality disorders (Craske & Stein, 2016).
Anxiety disorders, when untreated, tend to recur chronically. The recommendation is to treat psychological treatments, particularly cognitive behavioral therapy, and pharmacological treatments, particularly selective serotonin-reuptake inhibitors and serotonin-noradrenaline-reuptake inhibitors. The combination of the two drugs works more effectively. (Beesdo, Knappe, & Pine, 2009) Childhood and adolescence is the core risk phase for the development of anxiety symptoms and syndromes, ranging from transient mild symptoms to full-blown anxiety disorders (Beesdo, Knappe, & Pine, 2009)
      I learned from the information you gave about enhancing client medication dosing using cytochrome B450 and gene testing in checking how a person metabolizes medication. This client, her Celexa, was increased to 5mg because she was fast in metabolizing her pills. 
I will be very interested to learn her outcome.
Reference,
Beesdo, K., Knappe, S., & Pine, D. S. (2009). Anxiety and anxiety disorders in children and adolescents: Developmental issues and implications for DSM-V. The Psychiatric clinics of North America, 32(3), 483“524. https://doi.org/10.1016/j.psc.2009.06.002
Craske, M. G., & Stein, M. B. (2016). Anxiety. Lancet (London, England), 388(10063), 3048“3059. https://doi.org/10.1016/S0140-6736(16)30381-6